Blue light excitation full-band red light therapy spectrum double-cavity LED-VCSEL composite packaging structure

Abstract

The present application belongs to the technical field of biological lighting, and particularly relates to a blue light excitation full-waveband red light phototherapy spectrum double-cavity LED-VCSEL composite packaging structure, which adopts an integrated double-cavity isolation support structure, realizes double-light-path physical isolation through an integrated light-shielding barrier, and completely eliminates the problem of cross-light spectrum distortion. The first light-emitting cavity carries a blue light LED wafer in cooperation with a four-element differentiated fluorescent powder system, complementarily forming a 450nm-1200nm full-range continuous high-purity red light spectrum, which is suitable for the light therapy needs of human multi-layer tissues; the second light-emitting cavity is filled with no fluorescent powder and can be compatible with LED and VCSEL wafers, and is suitable for multi-waveband targeted light source packaging. The present application can realize three controllable light therapy modes of full-spectrum, precise targeting and composite superposition, has high structural integration, good spectral stability and excellent mass production consistency, effectively improves the biological light therapy effect, and is suitable for medical rehabilitation and home physiotherapy multi-scene applications.

Description

Technical Field

[0001] This invention belongs to the field of bio-lighting technology, and in particular relates to a dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum, which is especially suitable for medical and home use as a bio-red light therapy light source for skin repair, anti-inflammatory analgesia, microcirculation improvement, soft tissue rehabilitation, etc. Background Technology

[0002] Biophototherapy relies on specific wavelengths of visible and near-infrared light to stimulate human cell metabolism. Different depths of human tissue correspond to different spectral absorption characteristics: superficial epidermal tissue is adapted to the visible red light band, dermal tissue is adapted to the 800nm~900nm mid-near-infrared band, and deep subcutaneous fascia tissue is adapted to the long-wave near-infrared band above 1000nm. Continuous spectrum covering multiple gradient bands is the core foundation for achieving multi-level, high-precision biophototherapy.

[0003] Current commercial phototherapy LED and VCSEL packaging solutions generally suffer from numerous core technological defects, which greatly limit the integration, adaptability, and therapeutic effects of phototherapy equipment, as detailed below:

[0004] First, traditional single-cavity fluorescent phototherapy light sources have narrow spectral coverage, poor continuity, and limited therapeutic targets. Conventional single-bowl blue fluorescent LEDs are only paired with basic red and green phosphors, with an effective spectral coverage limit generally below 900nm, lacking the long-wave near-infrared band above 1000nm suitable for deep fascia repair. A few solutions that add infrared powder use only a single type of infrared phosphor, failing to differentiate the optical characteristics of mid-infrared and long-wave infrared powders, which easily leads to problems such as spectral breaks and energy dips in the band. They cannot form a smooth, unbroken red light spectrum from 450nm to 1200nm, and can only act on superficial skin tissue, with weak therapeutic effects on deep tissues. Furthermore, the purity of the red light is low, resulting in poor bio-photon utilization.

[0005] Secondly, the integration of broad-spectrum therapeutic light sources and targeted single-wavelength light sources cannot be miniaturized. To balance broad-spectrum repair across the entire area with targeted therapy at specific points, current technologies can only employ two independently packaged light sources assembled separately. This separate assembly structure results in large assembly tolerances, optical misalignment in the dual optical paths, and poor optical path consistency. Furthermore, the overall PCB wiring is cumbersome, and the modules are bulky, making it unsuitable for the development of portable, miniaturized phototherapy devices. Moreover, the costs of mold development, material warehousing, and assembly processes for two independent supports are significantly increased, leading to low product cost-effectiveness.

[0006] Third, the packaging brackets have poor versatility and cannot be compatible with both LED and VCSEL chips. There are significant differences between LED planar light-emitting chips and VCSEL vertical cavity surface-emitting chips in terms of light-emitting surface size, light emission angle, die bonding height, and pad compatibility specifications. Existing single-cavity and dual-cavity packaging brackets on the market are all single-adapter designs, which can only package conventional LED chips or VCSEL chips individually and cannot be universally adapted to both types of chips. If it is necessary to replace different types and different wavelengths of therapeutic chips, the bracket mold must be customized again, resulting in long product iteration cycles, high R&D costs, and limited compatibility scenarios.

[0007] Fourth, multi-path coexistence structures are prone to crosstalk interference and poor spectral stability. A small number of existing dual-cavity support systems use only a simple combination of dual monochromatic LEDs without a dedicated physical light-shielding isolation structure. This easily leads to stray light crosstalk when the two light sources are operating. If one cavity is filled with phosphor to achieve broadband conversion, the monochromatic stray light from the other cavity will continuously illuminate the phosphor layer, causing problems such as light color shift, color coordinate drift, and spectral distortion. This results in an inability to stably output the preset standard therapeutic spectrum, leading to poor product spectral yield and batch consistency.

[0008] In summary, the industry currently lacks an integrated, physically isolated composite packaging structure that cannot simultaneously achieve the technical effects of "single-chip excitation of full-domain continuous red light broadband, multi-type chip targeted adaptation, independent controllability of dual optical paths, and stable output of crosstalk spectrum," thus hindering the development of high-precision, integrated, and multi-scenario adaptable biophototherapy light source technology. Summary of the Invention

[0009] To address the inherent shortcomings of existing single-cavity LEDs, such as incomplete spectral coverage, poor spectral continuity, low integration of separate light sources, weak compatibility of support chips, crosstalk distortion in dual-path light sources, and poor product versatility, this invention provides a dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum. This structure aims to achieve a continuous, high-purity red light spectrum across the entire spectrum through a customized, differentiated multi-component phosphor ratio system. Combined with an integrated, cavity-isolated structure compatible with multiple types of optoelectronic chips, it enables multi-mode controllable phototherapy output, balancing miniaturization, versatility, spectral stability, and multi-level precise therapeutic effects.

[0010] To achieve the above objectives, this invention provides a dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum, comprising an integrated insulating packaging bracket, wherein the integrated insulating packaging bracket is formed with a first light-emitting cavity and a second light-emitting cavity that are independent of each other and physically isolated.

[0011] The first and second light-emitting cavities are respectively provided with independent die-bonding pads and independent external pins, and the two optical circuits are completely independently controlled; an integrated light-shielding and insulating barrier is provided between the first and second light-emitting cavities to achieve physical isolation of the two optical paths and eliminate cross-light interference.

[0012] The first light-emitting cavity is provided with a blue LED chip and filled with a quaternary composite fluorescent adhesive, which includes yellow-green phosphor, red phosphor, mid-infrared phosphor and long-wave infrared phosphor. The blue LED chip excites the yellow-green phosphor, red phosphor, mid-infrared phosphor and long-wave infrared phosphor to form a continuous phototherapy spectrum of 450nm~1200nm without discontinuity.

[0013] The second light-emitting cavity is a pure light-emitting cavity without phosphor, which can be simultaneously compatible with the packaging of LED chips and VCSEL vertical cavity surface emitter chips;

[0014] The first and second light-emitting cavities can be lit independently or simultaneously to achieve multi-mode controllable phototherapy output.

[0015] Optionally, the optical parameters of the quaternary composite fluorescent adhesive are configured as follows:

[0016] The yellow-green phosphor has an emission peak of 540nm~560nm and a half-wavelength of 70nm~105nm.

[0017] The red phosphor has an emission peak of 650nm~670nm and a half-wavelength of 70nm~105nm.

[0018] The mid-infrared phosphor has an emission peak of 800nm~860nm and a half-wavelength of 100nm~180nm.

[0019] The long-wave infrared phosphor has an emission peak of 1000nm~1060nm and a half-wavelength of 10nm~40nm.

[0020] Optionally, the mass ratio of each component of the quaternary composite fluorescent adhesive is as follows: transparent encapsulating adhesive: yellow-green phosphor: red phosphor: mid-infrared phosphor: long-wave infrared phosphor = 11: (12.5~13.5): (4.5~5.5): (1~2): (1.8~5.0).

[0021] Preferably, when the ratio of transparent encapsulating adhesive: yellow-green phosphor: red phosphor: mid-infrared phosphor: long-wave infrared phosphor = 11:12:5:1.5:3.4, a balanced global spectrum can be obtained;

[0022] When the ratio of the transparent encapsulating adhesive to yellow-green phosphor to red phosphor to mid-infrared phosphor to long-wave infrared phosphor is 11:12.5:4.5:1:1.8, it can increase the near-infrared radiation flux.

[0023] When the ratio of the transparent encapsulating adhesive to yellow-green phosphor to red phosphor to mid-infrared phosphor to long-wave infrared phosphor is 11:13.5:5.5:2:5.0, it can enhance the proportion of long-wave infrared energy.

[0024] Optionally, the cup depth of the first light-emitting cavity is greater than the cup depth of the second light-emitting cavity, and it can completely cover the blue LED chip and the composite phosphor layer.

[0025] Optionally, the blue LED chip is a 450nm~460nm blue LED chip. After exciting the quaternary composite phosphor, the main color of the output spectrum is pure red, the red light purity is not less than 90%, the main peak of visible light is located at 650nm~660nm, the main peak of near-infrared light is located at 1020nm~1030nm, and there are no impurities or energy dips in the entire wavelength range.

[0026] Optionally, the second light-emitting cavity can be compatible with the following types of LED chips: 590~600nm LED chips, 620~640nm LED chips, 650~670nm LED chips, 650~670nm VCSEL vertical cavity surface emitter chips, 810~830nm LED chips, 840~860nm LED chips, 840~860nm VCSEL vertical cavity surface emitter chips, 930~950nm LED chips, 930~950nm VCSEL vertical cavity surface emitter chips, 1050~1080nm LED chips, and 1050~1080nm VCSEL vertical cavity surface emitter chips.

[0027] Optionally, the multi-mode controllable phototherapy output includes three working modes:

[0028] Full-spectrum physiotherapy mode: The first light-emitting cavity is lit up individually to form a continuous broadband red light of 450nm~1200nm;

[0029] Precision-targeted physiotherapy mode: The second light-emitting cavity is lit up separately to form narrow-band single-wavelength light;

[0030] Composite superimposed physiotherapy mode: The first and second light-emitting cavities are lit up simultaneously to form a broadband continuous red light as the base, superimposed with targeted narrowband infrared light.

[0031] Optionally, the integrated insulating encapsulation bracket is integrally injection molded from PCT material.

[0032] Optionally, the quaternary composite fluorescent adhesive is prepared using a vacuum degassing and full-encapsulation curing process.

[0033] The blue light-excited full-band red light phototherapy spectrum dual-cavity LED-VCSEL composite packaging structure provided in this invention has at least one of the following technical effects:

[0034] First, this invention features a unique differentiated quaternary phosphor synergistic formulation system, breaking through the spectral limitations of traditional single-infrared powders. By distinguishing the differences in half-width and emission bands between mid-infrared and long-wave infrared powders, and combining this with precisely defined mass ratios, a single blue LED chip can achieve seamless, high-purity red light spectrum output across the entire 450nm-1200nm range. This completely solves the defects of traditional phototherapy light sources, such as spectral fragmentation, lack of near-infrared bands, low red light purity, and poor bioavailability. It also matches the absorption characteristics of multiple layers of human tissue, significantly improving the coverage and therapeutic effect of phototherapy. This customized phosphor formulation and spectral combination cannot be obtained through conventional limited experiments.

[0035] Secondly, this invention employs an integrated, multi-cavity light-shielding support structure, achieving miniaturized integration of the light source and resolving the pain points of separate assembly. Compared to traditional separate dual-light source combinations, this invention integrates the broadband conversion cavity and the target-compatible cavity onto the same support substrate, reducing the overall device volume by more than 40%, effectively meeting the needs of portable phototherapy devices. The integrated light-shielding isolation barrier completely isolates crosstalk from the dual optical paths at the physical level, eliminating spectral drift and color shift problems caused by monochromatic light contamination of the phosphor layer, significantly improving the product's spectral yield and batch spectral consistency, while simplifying assembly processes and reducing wiring and mold production costs.

[0036] Third, the second light-emitting cavity of this invention achieves universal compatibility between LED and VCSEL chips, greatly improving product versatility and iteration efficiency. Breaking through the limitations of traditional single-chip adaptation in scaffolds, by optimizing the cup height, die-bonding platform, and pad structure, it enables free switching between two types of optoelectronic chips and more than ten wavelength light sources, eliminating the need for repeated development of customized molds. This significantly shortens the R&D cycle for new phototherapy devices and adapts to diverse needs in various scenarios such as home care, medical rehabilitation, and joint pain relief.

[0037] Fourth, this invention features three independent and controllable working modes, making it highly adaptable to various scenarios. Breaking away from the limitation of traditional composite light sources that can only emit light synchronously, it allows for free switching between three working states: broad-spectrum repair across the entire area, precise targeting at a single point, and enhanced dual-light superposition. It balances basic maintenance with high-precision lesion treatment, covering all levels of phototherapy application scenarios, and its adaptability and functionality far exceed those of existing conventional phototherapy light sources.

[0038] Fifth, this invention has strong adaptability to mass production and excellent batch consistency. The optical parameters and ratio ranges of each phosphor are strictly cured, and with the combination of vacuum degassing and full-encapsulation curing processes, the fluctuations in the spectrum, color coordinates, and red light purity of mass-produced devices are minimal, eliminating the need for complex grading and screening. The overall structure is compatible with existing mature semiconductor packaging production lines, making industrial mass production easy and possessing extremely high industrialization value. Attached Figure Description

[0039] To more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0040] Figure 1 This is a schematic diagram of the overall structure of the integrated dual-cavity stent provided in an embodiment of the present invention.

[0041] Figure 2 The image shows the spectrum and electro-optical test pattern of the first light-emitting cavity in Embodiment 1 of the present invention.

[0042] Figure 3 This is the spectrum of the second light-emitting cavity 660mm in Embodiment 1 of the present invention.

[0043] Figure 4 This is a spectral diagram of the first light-emitting cavity in Embodiment 2 of the present invention.

[0044] Figure 5 This is the spectrum of the second light-emitting cavity 850mm in Embodiment 2 of the present invention.

[0045] Figure 6 This is a spectrum and electro-optical test diagram of the first light-emitting cavity in Embodiment 3 of the present invention.

[0046] Figure 7 This is the spectrum of the second light-emitting cavity 1064mm in Embodiment 3 of the present invention.

[0047] The following are the labeling elements in the figure:

[0048] 1—Blue LED chip 2—Targeted chip

[0049] 3—Bonding wire; 4—First light-emitting cavity

[0050] 5—Second light-emitting cavity; 6—Integrated insulating encapsulation bracket

[0051] 7—Integrated light-shielding and insulating barrier wall; 8—Positive electrode

[0052] 9—Negative electrode. Detailed Implementation

[0053] Embodiments of the present invention are described in detail below, examples of which are illustrated in the accompanying drawings, wherein the same or similar reference numerals denote the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are exemplary and intended to explain embodiments of the present invention, and should not be construed as limiting the present invention.

[0054] In one embodiment of the present invention, such as Figure 1 As shown, a dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum is provided, including an integrated insulating packaging bracket 6, wherein the integrated insulating packaging bracket 6 is formed with a first light-emitting cavity 4 and a second light-emitting cavity 5 that are independent and physically isolated from each other.

[0055] The first light-emitting cavity 4 and the second light-emitting cavity 5 are respectively provided with independent die-bonding pads and independent external pins to form positive electrode 8 and negative electrode 9, and the two optical circuits are completely independently controlled; an integrated light-shielding and insulating isolation barrier 7 is provided between the first light-emitting cavity 4 and the second light-emitting cavity 5 to realize physical isolation of the dual optical paths and eliminate cross-light interference.

[0056] The first light-emitting cavity 4 is provided with a blue LED chip 1 and filled with a quaternary composite fluorescent adhesive. The blue LED chip 1 is connected to the first light-emitting cavity 4 through a lead wire 3. The quaternary composite fluorescent adhesive includes yellow-green phosphor, red phosphor, mid-infrared phosphor and long-wave infrared phosphor. The blue LED chip 1 excites the yellow-green phosphor, red phosphor, mid-infrared phosphor and long-wave infrared phosphor to form a continuous phototherapy spectrum of 450nm~1200nm without discontinuity.

[0057] The second light-emitting cavity 5 is a pure light-emitting cavity without phosphor, which can simultaneously accommodate the packaging of LED chips and VCSEL vertical cavity surface emitter chips and other target chips 2. The target chip 2 is connected to the second light-emitting cavity 5 through leads 3.

[0058] The first light-emitting cavity 4 and the second light-emitting cavity 5 can be lit independently or simultaneously to achieve multi-mode controllable phototherapy output.

[0059] Furthermore, the optical parameters of the quaternary composite fluorescent adhesive are configured as follows:

[0060] The yellow-green phosphor has an emission peak of 540nm~560nm and a half-wavelength of 70nm~105nm.

[0061] The red phosphor has an emission peak of 650nm~670nm and a half-wavelength of 70nm~105nm.

[0062] The mid-infrared phosphor has an emission peak of 800nm~860nm and a half-wavelength of 100nm~180nm.

[0063] The long-wave infrared phosphor has an emission peak of 1000nm~1060nm and a half-wavelength of 10nm~40nm.

[0064] Furthermore, the mass ratio of each component in the quaternary composite fluorescent adhesive is as follows: transparent encapsulating adhesive: yellow-green phosphor: red phosphor: mid-infrared phosphor: long-wave infrared phosphor = 11: (12.5~13.5): (4.5~5.5): (1~2): (1.8~5.0).

[0065] Preferably, when the ratio of transparent encapsulating adhesive: yellow-green phosphor: red phosphor: mid-infrared phosphor: long-wave infrared phosphor = 11:12:5:1.5:3.4, a balanced full-range spectrum can be obtained; suitable for general skin full-layer repair scenarios;

[0066] When the ratio of the transparent encapsulating adhesive to yellow-green phosphor to red phosphor to mid-infrared phosphor to long-wave infrared phosphor is 11:12.5:4.5:1:1.8, it can increase the near-infrared radiation flux, making it suitable for deep pain relief scenarios in joints and muscles.

[0067] When the ratio of the transparent encapsulating adhesive to yellow-green phosphor to red phosphor to mid-infrared phosphor to long-wave infrared phosphor is 11:13.5:5.5:2:5.0, it can enhance the proportion of long-wave infrared energy. This is suitable for deep rehabilitation scenarios involving subcutaneous fascial strain.

[0068] Furthermore, the cup depth of the first light-emitting cavity 4 is greater than that of the second light-emitting cavity 5, and it can completely cover the blue LED chip 1 and the composite phosphor layer. Combined with an integrated light-shielding barrier, this completely avoids spectral drift, color coordinate shift, and spectral distortion caused by monochromatic stray light from the second light-emitting cavity 5 irradiating the phosphor.

[0069] Furthermore, the blue LED chip 1 adopts a 450nm~460nm blue LED chip 1. After exciting the quaternary composite phosphor, the main color of the output spectrum is pure red, the red light purity is not less than 90%, the main peak of visible light is located at 650nm~660nm, the main peak of near-infrared light is located at 1020nm~1030nm, and there are no impurities or energy dips in the entire wavelength range.

[0070] Furthermore, the second light-emitting cavity 5 can be compatible with the following chips: 590~600nm LED chips, 620~640nm LED chips, 650~670nm LED chips, 650~670nm VCSEL vertical cavity surface emitter chips, 810~830nm LED chips, 840~860nm LED chips, 840~860nm VCSEL vertical cavity surface emitter chips, 930~950nm LED chips, 930~950nm VCSEL vertical cavity surface emitter chips, 1050~1080nm LED chips, and 1050~1080nm VCSEL vertical cavity surface emitter chips.

[0071] In this invention, the multi-mode controllable phototherapy output includes three working modes:

[0072] Full-area broad-spectrum physiotherapy mode: The first light-emitting cavity 4 is lit up individually to form a continuous broad-spectrum red light of 450nm~1200nm; to achieve uniform repair and microcirculation regulation of the entire layer of human epidermis, dermis and subcutaneous fascia;

[0073] Precision-targeted physiotherapy mode: The second light-emitting cavity 5 is lit up separately to form narrow-band single-wavelength light; it can perform targeted anti-inflammatory, analgesic, and repair effects on local lesions and deep tissues;

[0074] Composite superimposed physiotherapy mode: The first light-emitting cavity 4 and the second light-emitting cavity 5 are lit simultaneously, forming a broadband continuous red light as the base, superimposed with targeted narrow-band infrared light. This enhances the depth and intensity of local physiotherapy.

[0075] Preferably, the integrated insulating encapsulation bracket 6 is integrally injection molded from PCT material. The dual-cavity die-bonding platform, pad structure, and cavity height have been optimized for compatibility, while also adapting to the differences in die-bonding and light-emitting structures of upright LEDs, flip-chip LEDs, and VCSEL chips.

[0076] More preferably, the quaternary composite fluorescent adhesive is prepared using a vacuum degassing and full-encapsulation curing process. The spectral parameters, color coordinates, and red light purity of batch devices fluctuate within 1.5%, and the photoelectric conversion efficiency remains stable at 38.5%~45.1%, demonstrating high batch consistency.

[0077] The blue light-excited full-band red light phototherapy spectrum dual-cavity LED-VCSEL composite packaging structure provided in this embodiment of the invention has the following advantages:

[0078] First, this invention features a unique differentiated quaternary phosphor synergistic formulation system, breaking through the spectral limitations of traditional single-infrared powders. By distinguishing the differences in half-width and emission bands between mid-infrared and long-wave infrared powders, and combining this with precisely defined mass ratios, a single blue LED chip can achieve seamless, high-purity red light spectrum output across the entire 450nm-1200nm range. This completely solves the defects of traditional phototherapy light sources, such as spectral fragmentation, lack of near-infrared bands, low red light purity, and poor bioavailability. It also matches the absorption characteristics of multiple layers of human tissue, significantly improving the coverage and therapeutic effect of phototherapy. This customized phosphor formulation and spectral combination cannot be obtained through conventional limited experiments.

[0079] Secondly, this invention employs an integrated, multi-cavity light-shielding support structure, achieving miniaturized integration of the light source and resolving the pain points of separate assembly. Compared to traditional separate dual-light source combinations, this invention integrates the broadband conversion cavity and the target-compatible cavity onto the same support substrate, reducing the overall device volume by more than 40%, effectively meeting the needs of portable phototherapy devices. The integrated light-shielding isolation barrier completely isolates crosstalk from the dual optical paths at the physical level, eliminating spectral drift and color shift problems caused by monochromatic light contamination of the phosphor layer, significantly improving the product's spectral yield and batch spectral consistency, while simplifying assembly processes and reducing wiring and mold production costs.

[0080] Third, the second light-emitting cavity 5 of this invention achieves universal compatibility between LED and VCSEL chips, greatly improving product versatility and iteration efficiency. Breaking through the limitations of traditional single-chip adaptation in support systems, by optimizing the cup height, die-bonding platform, and pad structure, it enables free switching between two types of optoelectronic chips and more than ten wavelength light sources, eliminating the need for repeated development of customized molds. This significantly shortens the R&D cycle for new phototherapy devices and adapts to diverse needs in various scenarios such as home care, medical rehabilitation, and joint pain relief.

[0081] Fourth, this invention features three independent and controllable working modes, making it highly adaptable to various scenarios. Breaking away from the limitation of traditional composite light sources that can only emit light synchronously, it allows for free switching between three working states: broad-spectrum repair across the entire area, precise targeting at a single point, and enhanced dual-light superposition. It balances basic maintenance with high-precision lesion treatment, covering all levels of phototherapy application scenarios, and its adaptability and functionality far exceed those of existing conventional phototherapy light sources.

[0082] Fifth, this invention has strong adaptability to mass production and excellent batch consistency. The optical parameters and ratio ranges of each phosphor are strictly cured, and with the combination of vacuum degassing and full-encapsulation curing processes, the fluctuations in the spectrum, color coordinates, and red light purity of mass-produced devices are minimal, eliminating the need for complex grading and screening. The overall structure is compatible with existing mature semiconductor packaging production lines, making industrial mass production easy and possessing extremely high industrialization value.

[0083] The following specific embodiments further illustrate the present invention.

[0084] Example 1.

[0085] Combination Figure 1 As shown, this embodiment provides a dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum, using an integrated PCT insulating packaging bracket; the first light-emitting cavity 4 has a 452.5-455nm blue LED chip 1 die-bonded, and the mass ratio of the quaternary composite fluorescent adhesive is: 11g transparent adhesive, 13g 550nm yellow-green phosphor, 5g 660nm red phosphor, 1.5g 830nm mid-infrared phosphor, and 1.95g 1026nm long-infrared phosphor; the half-widths of each powder are 85nm, 85nm, 140nm, and 22nm respectively; after thorough stirring and vacuum degassing, the fluorescent adhesive completely coats the blue LED chip 1 and is cured.

[0086] The first light-emitting cavity 4 is encapsulated with quaternary composite fluorescent adhesive; the second light-emitting cavity 5 is encapsulated with silicone resin adhesive.

[0087] Based on segmented spectral measurements, the first light-emitting cavity 4 in this embodiment 1 outputs a continuous red light spectrum from 450nm to 1200nm, without band breaks or extraneous peaks. The test report is shown in Table 1 below:

[0088]

[0089] Table 1

[0090] In this embodiment, the first light-emitting cavity 4 uses a 452.5-455nm blue LED chip 1 to excite a quaternary composite phosphor. The test current is about 20mA, the forward voltage is 2.67-2.69V, and the average is 2.68V; the luminous flux is 1.79-1.92lm, and the radiant flux Φe is 22.71-23.12mW, with an average of 22.92mW.

[0091] The device's color coordinates range from x-coordinates of 0.6078 to 0.6139 and from y-coordinates of 0.3744 to 0.3772, with averages of x=0.6114 and y=0.3758; color temperature ranges from 1281 to 1313 K; red light purity ranges from 95.40% to 96.80%, with an average of 96.32%; peak wavelength ranges from 654.20 to 656.60 nm, with an average of 655.45 nm; and photoelectric conversion efficiency ranges from 42.53% to 43.02%, with an average of 42.81%.

[0092] Combination Figure 1 As can be seen from the spectrum, it outputs a continuous red light spectrum from 450nm to 1200nm without spectral breaks or extraneous peaks. The main visible light peak is 654.4nm, and the main near-infrared peak is 1026.2nm. The electrical, optical, and colorimetric parameters have small batch dispersion and excellent spectral continuity, which can be matched to the phototherapy absorption windows of multiple tissues such as the epidermis, dermis, and subcutaneous fascia of the human body.

[0093] The second light-emitting cavity 5 encapsulates a 660nm VCSEL chip, capable of independently outputting 660nm targeted anti-inflammatory narrowband light. Its test report data is shown in Table 2 below:

[0094]

[0095] Table 2

[0096] like Figure 2 The image shows the 5660nm spectrum of the second light-emitting cavity in Embodiment 1. The second light-emitting cavity 5 in this embodiment encapsulates a 660nm VCSEL chip. The test current is approximately 9.98mA; the forward voltage is 2.110-2.120V, with an average forward voltage of 2.114V; the optical power is 21.05-21.15mW, with an average of 21.09mW; the radiant flux Φe is 3.44-4.78mW, with an average of 4.32mW; the peak wavelength is 663.2-665.4nm, with an average of 664.1nm; the half-width is 2.7-2.8nm, exhibiting excellent narrow-band spectral characteristics; and the photoelectric conversion efficiency is 16.3%-22.6%, with an average of 20.5%. The device exhibits minimal fluctuations in electrical and optical parameters and can output 660nm targeted anti-inflammatory narrow-band light, suitable for anti-inflammatory treatment of skin wounds and superficial tissue repair therapy.

[0097] This embodiment 1 can achieve three working modes: the first light-emitting cavity 4 can be turned on alone to complete the full-thickness broad-spectrum repair of the skin; the second light-emitting cavity 5 can be turned on alone to achieve precise anti-inflammatory physiotherapy of the wound; and the dual cavities can be lit up simultaneously to achieve physiotherapy with broad-spectrum base superimposed targeted light, which is suitable for medical wound repair scenarios.

[0098] This embodiment 1 is the optimal formulation and standard adaptation implementation scheme of the present invention. By limiting the precise intermediate ratio of the quaternary composite fluorescent adhesive, and combining it with a 452.5-455nm standard blue light excitation chip and a 660nm VCSEL chip, optimal matching of structure, spectrum, performance, and application scenarios is achieved, demonstrating strong technical demonstrativeness and versatility. Firstly, the precisely centered phosphor mass ratio ensures a balanced distribution of spectral energy in the 550nm yellow-green band, 660nm red band, 830nm mid-infrared band, and 1026nm long-wave infrared band, completely eliminating spectral breaks and energy dips across the entire 450nm-1200nm band. It stably achieves 95.6% ultra-high red light purity and standard color coordinate parameters. The dual main peaks of visible and near-infrared light are precisely positioned without interference from stray peaks, allowing simultaneous adaptation to the phototherapy absorption needs of all layers of human tissue, including the epidermis, dermis, and subcutaneous fascia, resulting in a balanced and excellent broad-spectrum therapeutic effect. Secondly, the 660nm VCSEL chip packaged in the second light-emitting cavity 5 features narrow-band light emission, high photoelectric conversion efficiency, and strong light output stability. Actual measurements show good consistency and small fluctuation range in the device's photoelectric parameters, enabling it to output a high-precision targeted anti-inflammatory narrow-band light source, providing precise therapeutic effects for skin wound inflammation and superficial tissue damage. Thirdly, this embodiment fully realizes the core functions of three controllable working modes. It can independently complete basic repair of the entire skin layer, achieve precise anti-inflammatory treatment of wounds, and enhance the therapeutic effect through dual-light superposition. It is perfectly adapted to mainstream core scenarios such as medical skin repair, wound anti-inflammatory treatment, and superficial microcirculation improvement. Furthermore, the process parameters are moderate, and the mass production stability is excellent, making it a standard mass production benchmark solution that effectively reduces parameter debugging costs and defect rates in mass production.

[0099] Example 2.

[0100] The structure of Example 2 is consistent with that of Example 1, the only difference being that the mass ratio of the quaternary composite fluorescent adhesive is set to the lower limit range: 11g of transparent adhesive, 12.5g of 550nm yellow-green phosphor, 4.5g of 660nm red phosphor, 1g of 830nm mid-infrared phosphor, and 5.0g of 1026nm long-infrared phosphor. The optical parameters of each powder remain unchanged. In this example, the spectral continuity and red light purity remain stable, and the near-infrared radiant flux reaches its peak, resulting in a more prominent deep tissue repair effect.

[0101] According to segmented spectral measurements, the first light-emitting cavity 4 in Example 2 outputs a continuous red light spectrum from 450nm to 1200nm, without band breaks or extraneous peaks. The test report is shown in Table 3 below:

[0102]

[0103]

[0104] Table 3

[0105] In this embodiment 2, the first light-emitting cavity 4 uses a quaternary composite phosphor with a lower limit of the ratio, which is excited by a 452.5-455nm blue LED chip 1. The test current is about 20mA, the forward voltage is 2.66-2.67V, and the average is 2.66V; the luminous flux is 1.79-1.92lm, and the radiant flux Φe is 23.66-24.07mW, with an average of 23.87mW.

[0106] The device's color coordinates range from x-coordinates of 0.5784 to 0.5857 and from y-coordinates of 0.3912 to 0.3938, with averages of x=0.5811 and y=0.3924; color temperature ranges from 1491 to 1542 K; red light purity ranges from 91.60% to 93.20%, with an average of 92.22%; peak wavelength ranges from 654.20 to 656.60 nm, with an average of 655.45 nm; and photoelectric conversion efficiency ranges from 44.56% to 45.04%, with an average of 44.83%.

[0107] Combination Figure 3 As can be seen from the spectrum, it outputs a continuous red light spectrum from 450nm to 1200nm without band breaks or extraneous peaks. The electrical, optical and colorimetric parameters have small batch fluctuations, and the spectral continuity meets the requirements for use in biological phototherapy. Under the premise of controlling the cost of phosphor materials, it can realize phototherapy irradiation of multiple tissues in the human body.

[0108] In this embodiment 2, the second light-emitting cavity 5 encapsulates an 850nm VCSEL chip. The 850nm near-infrared light has excellent penetration into muscles and joints, making it suitable for deep pain relief physiotherapy of limbs and joints. The test data is shown in Table 4 below:

[0109]

[0110] Table 4

[0111] like Figure 4 The image shows the 5850nm spectrum of the second light-emitting cavity in Embodiment 2. The second light-emitting cavity 5 in this embodiment encapsulates an 850nm VCSEL chip. The test current is approximately 20mA. The device forward voltage is 1.897-1.916V, with an average forward voltage of 1.902V; the optical power is 37.95-38.35mW, with an average of 38.06mW; the radiant flux Φe is 16.33-17.54mW, with an average of 17.14mW; the peak wavelength is 847.9-850.7nm, with an average of 849.0nm; the half-width at half-maximum (WW) is stable at 2.9nm, and the emission spectrum is narrow; the photoelectric conversion efficiency is 43.0%-46.1%, with an average of 45.0%. The device exhibits small dispersion in its electrical and optical parameters, outputs narrow-band 850nm near-infrared light, and has strong penetration ability into muscle and joint tissues, making it suitable for deep analgesia therapy of limbs and joints.

[0112] This embodiment 2 can achieve three working modes: the first light-emitting cavity 4 can be turned on alone to complete the broad-spectrum repair of the whole layer of skin; the second light-emitting cavity 5 can be turned on alone to achieve deep targeted analgesia physiotherapy of joints and muscles; the dual cavities can be lit up simultaneously to achieve a broad-spectrum substrate superimposed with 850nm targeted infrared light for rehabilitation physiotherapy, which is suitable for deep analgesia physiotherapy of limbs and joints.

[0113] This embodiment 2 uses the lower limit parameters of the quaternary composite fluorescent adhesive ratio. Compared with the optimal embodiment, it optimizes the cost of powder materials while ensuring the stability of core spectral performance. It is also suitable for deep joint physiotherapy scenarios, demonstrating outstanding scenario-specificity and economic practicality. Firstly, even with the lower limit range for each fluorescent powder ratio, the complementary characteristics of the differentiated powder optical parameters can still maintain a continuous, uninterrupted red light spectrum output across the entire 450nm-1200nm range. The core indicators of red light purity, color coordinates, and spectral continuity show no significant attenuation, fully meeting the basic performance requirements of conventional biophototherapy and ensuring that the product's core therapeutic functions are not compromised. Secondly, in this embodiment, the second light-emitting cavity 5 is adapted to encapsulate an 850nm VCSEL chip. Near-infrared light in this band has the characteristics of deep penetration and high soft tissue absorption, effectively penetrating human muscles and joint connective tissue, precisely targeting deep lesions in the limbs and joints. This specifically achieves joint pain relief, muscle strain relief, and improvement of deep soft tissue microcirculation, overcoming the limitation of conventional short-wave red light in deep joint therapy. This greatly expands the applicability of this invention in specific scenarios such as sports rehabilitation, bone and joint maintenance, and chronic joint pain therapy. Thirdly, the lower limit of the powder ratio effectively reduces the amount of expensive infrared phosphor used. While ensuring the product's therapeutic performance meets standards and spectral stability is qualified, it significantly reduces the cost of encapsulation materials, improves the product's cost-effectiveness, and is more suitable for the mass production and widespread application of home-use phototherapy devices, demonstrating significant advantages for industrialization.

[0114] Example 3.

[0115] The structure of Example 3 is the same as that of Example 1, except that the mass ratio of the quaternary composite fluorescent adhesive is taken to the upper limit range: 11g of transparent adhesive, 13.5g of 550nm yellow-green phosphor, 5.5g of 660nm red phosphor, 2g of 830nm mid-infrared phosphor, and 3g of 1030nm long-infrared phosphor. The optical parameters of each powder remain unchanged.

[0116] According to segmented spectral measurements, the first light-emitting cavity 4 in Example 3 outputs a continuous red light spectrum from 450nm to 1200nm, without band breaks or extraneous peaks. The test report is shown in Table 5 below:

[0117]

[0118] Table 5

[0119] In this embodiment, the third light-emitting cavity uses a quaternary composite phosphor with the upper limit of the ratio, which is excited by a 452.5-455nm blue LED chip 1. The test current is about 15mA; the forward voltage is 2.69-2.82V, with an average of 2.73V; the luminous flux is 1.56-1.69lm, and the radiant flux Φe is 15.78-16.59mW, with an average of 16.11mW.

[0120] The device's color coordinates range from x-coordinates of 0.6041 to 0.6105 and from y-coordinates of 0.3740 to 0.3800, with averages of x=0.6062 and y=0.3771; color temperature ranges from 1291 to 1342 K; red light purity ranges from 94.40% to 96.00%, with an average of 95.18%; peak wavelength ranges from 653.20 to 656.60 nm, with an average of 654.73 nm; and photoelectric conversion efficiency ranges from 38.52% to 40.85%, with an average of 39.22%.

[0121] Combination Figure 5 As can be seen from the spectrum, the output is a continuous red light spectrum from 450nm to 1200nm, without band breaks or extraneous peaks. In this embodiment, the phosphor ratio is set to the upper limit, the energy ratio of the long-wave near-infrared band is increased, the batch dispersion of electrical and color parameters is small, the output of phototherapy for deep tissues is enhanced, and it is suitable for rehabilitation and physiotherapy scenarios of subcutaneous fascia strain.

[0122] In this embodiment, the second light-emitting cavity 5 encapsulates a 1060nm LED chip, suitable for rehabilitation therapy scenarios involving subcutaneous fascia strain. Test data is shown in Table 6 below:

[0123]

[0124] Table 6

[0125] like Figure 6 The image shows the 51064nm spectrum of the second light-emitting cavity in Embodiment 3 of the present invention. In this embodiment, the second light-emitting cavity 5 encapsulates a 1060nm LED chip, with a test current of approximately 14.99mA; the device forward voltage is 1.811-1.835V, with an average forward voltage of 1.824V; the radiant flux Φe is 10.83-11.35mW, with an average of 11.18mW; the peak wavelength is 1065.6-1068.3nm, with an average of 1067.13nm; the half-width is 8.7-8.8nm, indicating a narrow spectral bandwidth; and the photoelectric conversion efficiency is 39.89%-41.69%, with an average of 40.9%. The device exhibits small dispersion in its electrical and optical parameters, outputs long-wave near-infrared narrow-band light, and possesses good penetration ability into subcutaneous fascia tissue, making it suitable for rehabilitation and physiotherapy of subcutaneous fascia strain.

[0126] This embodiment 3 can realize three working modes: the first light-emitting cavity 4 can be turned on alone to complete the full-thickness skin broad-spectrum repair; the second light-emitting cavity 5 can be turned on alone to realize the targeted rehabilitation therapy for subcutaneous fascia strain; the dual cavities can be lit up simultaneously to realize the rehabilitation therapy of broad-spectrum base superimposed 1060nm targeted infrared light, which is suitable for the human subcutaneous fascia strain rehabilitation therapy scenario.

[0127] This embodiment 3 employs the upper limit parameter of the quaternary composite fluorescent adhesive ratio, focusing on enhancing the energy of the long-wave near-infrared spectrum and targeting the rehabilitation and physiotherapy of deep fascia tissues in the human body. It possesses the technical advantages of outstanding targeting performance and significant deep physiotherapy effects. Firstly, by increasing the upper limit of the ratio of mid-infrared and long-wave infrared fluorescent powders, the spectral radiant flux and energy ratio of the long-wave near-infrared band above 1000nm are significantly increased. This enhances the spectral matching degree of deep tissues such as subcutaneous fascia and deep muscles, effectively solving the industry pain points of insufficient deep energy and weak fascia repair effect of traditional phototherapy light sources. It has excellent repair and physiotherapy effects on problems such as subcutaneous fascia stiffness, deep soft tissue damage, and chronic blockage caused by long-term strain. Secondly, the second light-emitting cavity 5, equipped with a 1060nm LED long-wave infrared chip, forms a spectral energy superposition with the first light-emitting cavity 4's broad-spectrum long-wave infrared band, further enhancing the intensity of deep tissue photostimulation. This creates a unique physiotherapy mode of "full-area broad-spectrum base + long-wave targeted enhancement," which is differentiated for high-end rehabilitation physiotherapy scenarios such as deep fascial strain and chronic soft tissue injury, filling the technological gap where conventional broad-spectrum phototherapy cannot achieve deep and precise enhanced physiotherapy. Thirdly, the fixed upper limit ratio process parameters in this embodiment are stable and controllable. Combined with an integrated cavity isolation structure, there is no crosstalk interference and no spectral distortion. After mass production, the product's deep physiotherapy performance is highly consistent, accurately adapting to the development needs of high-end medical rehabilitation equipment and professional physiotherapy instruments, significantly enhancing the product's high-end application value and market competitiveness.

[0128] The three embodiments of this invention are based on the same integrated dual-cavity isolation stent structure, all of which overcome the inherent defects of the prior art and possess unified core technological advantages and industrialization value. First, all adopt an integrated light-shielding isolation barrier physical cavity structure, completely eliminating crosstalk interference between dual optical paths, effectively avoiding spectral drift, color shift, and spectral distortion caused by stray light irradiation of the phosphor layer, and significantly improving product spectral yield and batch consistency. Second, the second light-emitting cavity 5 achieves universal compatibility with LED and VCSEL chips, allowing free switching of chip type and emission band according to different physiotherapy scenarios, without the need for re-customizing stent molds, shortening product iteration cycles and reducing R&D costs. Third, all three embodiments support three independent and controllable physiotherapy working modes, flexibly adapting to different needs such as basic maintenance, precise targeted physiotherapy, and rehabilitative physiotherapy, with a wide range of scenario adaptability. Fourth, the processes of all embodiments are compatible with existing mature semiconductor packaging production lines, with simple and highly controllable production processes, no special complex procedures, low difficulty in industrial mass production, and extremely high industrialization and promotion value.

[0129] This invention possesses significant substantive features and remarkable progress compared to existing technologies, specifically:

[0130] 1. Existing technology is a conventional single-cavity blue light fluorescent phototherapy LED light source. This type of technology only sets up a single light-emitting cavity, the phosphor composition is single and the ratio is wide, it cannot achieve continuous red light spectrum output of 450nm-1200nm, there is no cavity isolation structure, it cannot be compatible with VCSEL chips, and it can only output a fixed single spectrum. It does not have the core technical features provided by this invention.

[0131] 2. This invention comprises two core innovative modules. The first is a unique quaternary differentiated half-wavelength phosphor formulation system, which achieves a continuous high-purity red light spectrum across the entire spectrum, which cannot be achieved by conventional formulations in the industry, through the complementary optical properties of multiple powders. The second is a pioneering differentiated dual-cavity isolation structure, which integrates a broadband spectrum conversion cavity and a universal targeting cavity for LEDs / VCSELs, enabling independent and controllable dual optical paths and crosstalk-free collaborative operation, thus solving the long-standing spectral defects and structural limitations of existing technologies.

[0132] 3. Existing single-cavity fluorescent light sources only use a single infrared powder ratio, without the technical approach of differentiated half-bandwidth powder synergistic matching and precise range ratio. The fluorescent formula of this invention requires a large number of orthogonal experiments for screening and optimization, which cannot be easily obtained by conventional limited experiments in this field. Existing dual-cavity supports are all dual monochromatic LED combination designs, without the differentiated cavity design approach of "broadband fluorescence conversion cavity + VCSEL compatible targeting cavity". At the same time, the industry generally ignores the distortion effect of crosstalk between dual optical paths on the fluorescence spectrum, and there is no technical inspiration for a matching integrated light-shielding and isolation structure.

[0133] 4. This invention is not a simple superposition of existing technical features. It organically combines customized full-domain red light broadband technology, dual-cavity isolation integration technology, and multi-type chip universal compatibility technology. At the same time, it solves multiple technical pain points of traditional light sources, such as incomplete spectrum, weak therapeutic effect, low integration, poor versatility, and unstable spectrum. It realizes full-domain broadband, precise targeting, and compound superposition of multi-mode controllable phototherapy output. It achieves comprehensive technical effects of miniaturization, high precision, and full-scene adaptability that cannot be achieved by existing technologies, and has extremely high innovation and industrialization value.

[0134] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum, characterized in that, It includes an integrated insulating encapsulation bracket, wherein the integrated insulating encapsulation bracket is formed with a first light-emitting cavity and a second light-emitting cavity that are independent and physically isolated from each other; The first and second light-emitting cavities are respectively provided with independent die-bonding pads and independent external pins, and the two optical circuits are completely independently controlled; an integrated light-shielding and insulating barrier is provided between the first and second light-emitting cavities to achieve physical isolation of the two optical paths and eliminate cross-light interference. The first light-emitting cavity is provided with a blue LED chip and filled with a quaternary composite fluorescent adhesive, which includes yellow-green phosphor, red phosphor, mid-infrared phosphor and long-wave infrared phosphor. The blue LED chip excites the yellow-green phosphor, red phosphor, mid-infrared phosphor and long-wave infrared phosphor to form a continuous phototherapy spectrum of 450nm~1200nm without discontinuity. The second light-emitting cavity is a pure light-emitting cavity without phosphor, which can be simultaneously compatible with the packaging of LED chips and VCSEL vertical cavity surface emitter chips; The first and second light-emitting cavities can be lit independently or simultaneously to achieve multi-mode controllable phototherapy output.

2. The dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum as described in claim 1, characterized in that: The optical parameters of the quaternary composite fluorescent adhesive are configured as follows: The yellow-green phosphor has an emission peak of 540nm~560nm and a half-wavelength of 70nm~105nm. The red phosphor has an emission peak of 650nm~670nm and a half-wavelength of 70nm~105nm. The mid-infrared phosphor has an emission peak of 800nm~860nm and a half-wavelength of 100nm~180nm. The long-wave infrared phosphor has an emission peak of 1000nm~1060nm and a half-wavelength of 10nm~40nm.

3. The dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum as described in claim 1, characterized in that: The mass ratio of each component in the quaternary composite fluorescent adhesive is as follows: transparent encapsulating adhesive: yellow-green fluorescent powder: red fluorescent powder: mid-infrared fluorescent powder: long-wave infrared fluorescent powder = 11: (12.5~13.5): (4.5~5.5): (1~2): (1.8~5.0).

4. The dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum as described in claim 3, characterized in that: When the ratio of the transparent encapsulating adhesive to yellow-green phosphor to red phosphor to mid-infrared phosphor to long-wave infrared phosphor is 11:12:5:1.5:3.4, a balanced global spectrum can be obtained. When the ratio of the transparent encapsulating adhesive to yellow-green phosphor to red phosphor to mid-infrared phosphor to long-wave infrared phosphor is 11:12.5:4.5:1:1.8, it can increase the near-infrared radiation flux. When the ratio of the transparent encapsulating adhesive to yellow-green phosphor to red phosphor to mid-infrared phosphor to long-wave infrared phosphor is 11:13.5:5.5:2:5.0, it can enhance the proportion of long-wave infrared energy.

5. The dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum as described in claim 1, characterized in that: The cup depth of the first light-emitting cavity is greater than that of the second light-emitting cavity, and it can completely cover the blue LED chip and the composite phosphor layer.

6. The dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum as described in claim 1, characterized in that: The blue LED chip uses a 450nm~460nm blue LED chip. After exciting the quaternary composite phosphor, the main color of the output spectrum is pure red, the red light purity is not less than 90%, the main peak of visible light is located at 650nm~660nm, the main peak of near-infrared light is located at 1020nm~1030nm, and there are no impurities or energy dips in the entire wavelength range.

7. The dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum as described in claim 1, characterized in that: The second light-emitting cavity can be compatible with the following chips: 590~600nm LED chips, 620~640nm LED chips, 650~670nm LED chips, 650~670nm VCSEL vertical cavity surface emitter chips, 810~830nm LED chips, 840~860nm LED chips, 840~860nm VCSEL vertical cavity surface emitter chips, 930~950nm LED chips, 930~950nm VCSEL vertical cavity surface emitter chips, 1050~1080nm LED chips, and 1050~1080nm VCSEL vertical cavity surface emitter chips.

8. The dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum according to claim 1, characterized in that: The multi-mode controllable phototherapy output includes three working modes: Full-spectrum physiotherapy mode: The first light-emitting cavity is lit up individually to form a continuous broadband red light of 450nm~1200nm; Precision-targeted physiotherapy mode: The second light-emitting cavity is lit up separately to form narrow-band single-wavelength light; Composite superimposed physiotherapy mode: The first and second light-emitting cavities are lit up simultaneously to form a broadband continuous red light as the base, superimposed with targeted narrowband infrared light.

9. The dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum according to claim 1, characterized in that: The integrated insulating encapsulation bracket is integrally injection molded from PCT material.

10. The dual-cavity LED-VCSEL composite packaging structure with blue light excitation and full-band red light phototherapy spectrum according to claim 1, characterized in that: The quaternary composite fluorescent adhesive is prepared using a vacuum degassing and full-encapsulation curing process.

Images